Sparian Biosciences Inc.
New York, NY Doing business as Palion Therapeutics
- UEI
- E6GKXJ7MWV68
- CAGE
- 8EU60
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 245 W 99th St 8b 615, New York, NY 10025, USA
- Website
- sparianbiosciences.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Clinical development of SBS-147: first-in-class oral arylepoxamide agonist for pain - abstract pain, both acute and… | National Institute on Drug Abuse | $9,360,586 | |
| Development of SBS-226, a MOR agonist / DOR antagonist, for OUD - abstract opioid use disorder (OUD) is a chronic… | National Institute on Drug Abuse | $19,841,335 | |
| Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder - abstract the growing… | National Institute on Drug Abuse | $23,597,485 | |
| Development of CP-analogs as novel treatments for opioid use disorder. - abstract opioid use disorder (OUD) is a chronic… | National Institute on Drug Abuse | $955,406 | |
| Arylepoxamides: a new class of potent, safer analgesics - the expansion of opioid prescribing in recent years to… | National Institute on Drug Abuse | $32,053,834 |
About Sparian Biosciences Inc.
Sparian Biosciences Inc., doing business as Palion Therapeutics, is a for-profit corporate entity registered in the System for Award Management (SAM) and located in New York City. The company focuses on developing novel pharmaceutical compounds targeting critical medical challenges, particularly in the realm of pain management and substance use disorders. Registered since September 2019, Palion Therapeutics specializes in researching and developing innovative therapeutic compounds that aim to provide alternative treatments to traditional opioid-based medications.
Through federal grant awards from the National Institute on Drug Abuse (NIDA), Sparian Biosciences has been pursuing multiple research and development projects targeting significant public health issues. The company has received substantial cooperative agreement grants to develop compounds like SBS-147 (a non-opioid pain treatment), SBS-226 (a potential treatment for opioid use disorder), and SBS-518 (a potential treatment for stimulant use disorder). These grants, ranging from approximately $3.1 million to $11.8 million, support preclinical and early clinical development stages, including Phase 1 safety studies and proof-of-concept trials. The research focuses on creating novel pharmaceutical interventions that could potentially mitigate the opioid epidemic by developing alternative pain management and addiction treatment solutions. Additionally, the company has engaged in sub-grant work with research institutions like Sloan-Kettering Institute for Cancer Research, demonstrating a collaborative approach to advancing pharmaceutical research in critical medical domains.
Quick answers
What is Sparian Biosciences Inc.'s UEI?
Sparian Biosciences Inc.'s Unique Entity ID (UEI) in SAM.gov is E6GKXJ7MWV68.
What is Sparian Biosciences Inc.'s CAGE code?
Sparian Biosciences Inc.'s CAGE code is 8EU60.
What is Sparian Biosciences Inc.'s primary NAICS code?
Sparian Biosciences Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Sparian Biosciences Inc. located?
Sparian Biosciences Inc.'s physical address in SAM.gov is 245 W 99th St 8b 615, New York, NY 10025, USA.
Is Sparian Biosciences Inc. registered in SAM.gov?
Yes. Sparian Biosciences Inc.'s SAM.gov registration is active through December 16, 2026.
What is Sparian Biosciences Inc.'s most recent federal award?
Sparian Biosciences Inc.'s most recent federal grant award is Clinical development of SBS-147: first-in-class oral arylepoxamide agonist for pain - abstract pain, both acute and… (UG3DA064392), from National Institute on Drug Abuse, on July 1, 2025.
On GovTribe
See Sparian Biosciences Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors